Intact proinsulin and β-cell function in lean and obese subjects with and without type 2 diabetes

Diabetes Care

Volumn 22, Issue 4, 1999, Pages 609-614

  Røder, Michael E ^a   Dinesen, Bo ^b   Hartling, Svend G ^b   Houssa, Paule ^b   Vestergaard, Henrik ^b   Sodoyez Goffaux, Françoise ^b   Binder, Christian ^b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; GLUCAGON; INSULIN; PROINSULIN;

ADULT; ARTICLE; CELL SECRETION; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC OBESITY; DIET RESTRICTION; DISEASE ASSOCIATION; HORMONE DETERMINATION; HUMAN; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL FUNCTION; PATHOPHYSIOLOGY; PROVOCATION TEST;

EID: 0033066241     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.22.4.609     Document Type: Article

References (43)

1. DeFronzo RA, Bonadonna RC, Ferrannini E: Pathogenesis of NIDDM: a balanced overview. Diabetes Care 15:318-368, 1992
2. Porte D Jr: β-cells in type 2 diabetes mellitus. Diabetes 40:166-180, 1991
3. Ward WK, Bolgiano DC, McKnight B, Halter JB, Porte D Jr: Diminished B cell secretory capacity in patients with non-insulin-dependent diabetes mellitus. J Clin Invest 74: 1318-1328, 1984
4. Faber OK, Binder C: C-peptide response to glucagon: a test for the residual β-cell function in diabetes mellitus. Diabetes 26:605-610, 1977
5. Pedersen O: The impact of obesity on the pathogenesis of non-insulin-dependent diabetes mellitus: a review of current hypotheses. Diabetes Metab Rev 5:495-509, 1989
6. Amer P, Pollare T, Lithell H: Different aetiologies of type 2 (non-insulin-dependent) diabetes mellitus in obese and non-obese subjects. Diabetologia 34:483-487, 1991
7. Fujimoto WY: Overview of non-insulin dependent diabetes mellitus (NIDDM) in different population groups. Diabet Med 13:S7-S10, 1996
8. Gordon P, Hendricks CM, Roth J: Circulating proinsulin-like component in man: increased proportion in hypoinsulinemic states. Diabetologia 10:469-474, 1974
9. Saad MF, Kahn SE, Nelson RG, Pettitt DJ, Knowler WC, Schwartz MW, Kowalyk S, Bennett PH, Porte D Jr: Disproportionately elevated proinsulin in Pima indians with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 70:1247-1253, 1990
10. Røder ME, Vaag A, Hartling SG, Dinesen B, Lanng S, Beck-Nielsen H, Binder C: Proinsulin immunoreactivity in identical twins discordant for noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 80:2359-2363, 1995
11. Kahn SE, McCulloch DK, Schwartz MW, Palmer JP, Porte D Jr: Effect of insulin resistance and hyperglycemia on proinsulin release in a primate model of diabetes mellitus. J Clin Endocrinol Metab 74:192-197, 1992
12. Kahn SE, Beard JC, Schwartz MW, Ward WK, Ding HL, Bergman RN, Taborsky GJ, Porte D Jr: Increased β-cell secretory capacity as mechanism for islet adaptation to nicotinic acid-induced insulin resistance. Diabetes 38:562-568, 1989
13. Koivisto VA, Yki-Järvinen H, Hartling SG, Pelkonen R: The effect of exogenous hyperinsulinemia on proinsulin secretion in normal man, obese subjects, and patients with insulinoma. J Clin Endocrinol Metab 63:1117-1120, 1986
14. Røder ME, Porte D Jr, Schwartz RS, Kahn SE: Disproportionately elevated proinsulin levels reflect the degree of impaired B-cell secretory capacity in patients with non-insulin dependent diabetes mellitus. J Clin Endocrinol Metab 83:604-608, 1998
15. Sobey WJ, Beer SF, Carrington CA, Clark PMS, Frank BH, Gray IP, Luzio SD, Owens DR, Schneider AE, Siddle K, Temple RC, Hales CN: Sensitive and specific two-site immunoradiometric assays for human insulin, proinsulin, 65-66 split and 32-33 split proinsulins. Biochem J 260:535-541, 1989
16. Linde S, Røder ME, Hartling SG, Binder C, Welinder BS: Separation and quantitation of serum proinsulin and proinsulin intermediates in humans. J Chromatogr 548:371-380, 1991
17. Ostrega D, Polonsky K, Nagi D, Yudkin J, Cox LJ, Clark PMS, Hales CN: Measurement of proinsulin and intermediates: validation of immunoassay methods by high-performance liquid chromatography, Diabetes 44:437-440, 1995
18. Hother-Nielsen O, Faber O, Sorensen NS, Beck-Nielsen H: Classification of newly diagnosed diabetic patients as insulin-requiring or non-insulin-requiring based on clinical and biochemical variables. Diabetes Care 11:531-537, 1988
19. Ward WK, Bolgiano DC, McKnight B, Halter JB, Porte D Jr: Diminished B cell secretory capacity in patients with non-insulin-dependent diabetes mellitus. J Clin Invest 74:1318-1328, 1984
20. World Health Organization: Diabetes Mellitus: Report of a WHO Study Group. Geneva, World Health Org., 1985 (Tech. Rep. Ser., no. 727)
21. Knip M, Vähäsalo P, Karjalainen J, Lounamaa R, Åkerblom HK, Childhood Diabetes in Finland Study Group: Natural history of preclinical IDDM in high risk siblings. Diabetologia 37:388-393, 1994
22. Kjems LL, Røder ME, Dinesen B, Hartling SG, Jorgensen PN, Binder C: Highly sensitive enzyme immunoassay of proinsulin immunoreactivity with use of two monoclonal antibodies. Clin Chem 39:2146-2150, 1993
23. Houssa P, Dinesen B, Deberg M, Frank BH, Van Schravendijk C, Sodoyez-Goffaux F, Sodoyez JC: First direct assay for intact human proinsulin. Clin Chem 44:1514-1519, 1998
24. Andersen L. Dinesen B, Jorgensen PN, Poulsen F, Røder ME: Enzyme immunoassay for intact human insulin in serum or plasma. Clin Chem 39:578-582, 1993
25. Heding LG: Radioimmunological determination of human C-peptide in serum. Diabetologia 11:541-548, 1975
26. Faber OK, Markussen J. Naithani VK, Binder C: Production of antisera to synthetic benzyloxycarbonyl-C-peptide of human proinsulin. Hoppe Seylers Z Physiol Chem 357:751-757, 1976
27. Røder ME, Vissing H, Nauck MA: Hyperproinsulinemia in a three-generation Caucasian family due to mutant proinsulin (Arg656His) not associated with impaired glucose tolerance: the contribution of mutant proinsulin to insulin bioactivity. J Clin Endocrinol Metab 81:1634-1640, 1996
28. Temple RC, Luzio SD, Schneider AE, Carrington CA, Owens DR, Sobey WJ, Hales CN: Insulin deficiency in non-insulin-dependent diabetes. Lancet i:293-295, 1989
29. Ward WK, LaCava EC, Paquette TL, Beard JC, Wallum BJ, Porte D Jr: Disproportionate elevation of immunoreactive proinsulin in type 2 (non-insulin-dependent) diabetes mellitus and in experimental insulin resistance. Diabetologia 30:698-702, 1987
30. Ward WK, Paquette TL, Frank BH, Porte D Jr: A sensitive radioimmunoassay for human proinsulin, with sequential use of antisera to C-peptide and insulin. Clin Chem 32:728-733, 1986
31. Hartling SG, Dinesen B, Kappelgård AM, Faber OK. Binder C: ELISA for human proinsulin. Clin Chim Acta 156:289-298, 1986
32. Cohen RM, Given BD, Licinio-Paixao J, Provow SA, Rue PA, Frank BH, Root MA, Polonsky KS, Tager HS, Rubenstein AH: Proinsulin radioimmunoassay in the evaluation of insulinomas and familial hyperproinsulinemia. Metabolism 35:1137-1146, 1986
33. Bowsher RR, Wolny JD, Frank BH: A rapid and sensitive radioimmunoassay for the measurement of proinsulin in human serum. Diabetes 41:1084-1090, 1992
34. Alpha B, Cox L, Crowther N, Clark PMS, Hales CN: Sensitive amplified immunoenzymometric assays (IEMA) for human insulin and intact proinsulin. Eur J Clin Chem Clin Biochem 30:27-32, 1992
35. Chevenne D, Riuz J, Lohmann L, Laudat A, Leblanc H, Gray IP, Passa P, Porquet D: Immunoradiometric assay of human intact proinsulin applied to patients with type 2 diabetes, impaired glucose tolerance, and hyperandrogenism. Clin Chem 40:754-757, 1994
36. Clark PM, Levy JC, Cox L, Burnett M, Turner RC, Hales CN: Immunoradiometric assay of insulin, intact proinsulin and 32-33 split proinsulin and radioimmunoassay of insulin in diet-treated type 2 (non-insulin-dependent) diabetic subjects. Diabetologia 35:469-474, 1992
37. Kahn SE, Halban PA: Release of incompletely processed proinsulin is the cause of the disproportionate proinsulinemia of NIDDM. Diabetes 46:1725-1732, 1997
38. Hartling SG, Røder ME, Dinesen B, Binder C: Proinsulin, C-peptide, and insulin in normal subjects during an 8-h hyperglycemic clamp. Eur J Endocrinol 134:197-200, 1996
39. Nauck MA, Siegel EG, Creutzfeldt W: Prolonged maximal stimulation of insulin secretion in healthy subjects does not provoke preferential release of proinsulin. Pancreas 6:645-652, 1991
40. Davies MJ, Metcalfe J, Day JL, Grenfell A, Hales CN, Gray IP: Improved beta cell function, with reduction in secretion of intact and 32/33 split proinsulin, after dietary intervention in subjects with type 2 diabetes mellitus. Diabet Med 11:71-78, 1994
41. Nagi DK, Mohamed Ali V, Yudkin JS: Effect of metformin on intact proinsulin and des 31,32 proinsulin concentrations in subjects with non-insulin-dependent (type 2) diabetes mellitus. Diabet Med 13:753-757, 1996
42. Davies MJ, Metcalfe J, Day JL, Grenfell A, Hales CN, Gray IP: Effect of sulphonylurea therapy on plasma insulin, intact and 32/33 split proinsulin in subjects with type 2 diabetes mellitus Diabet Med 10:293-298, 1993
43. Rachman J, Levy JC, Barrow BA, Manley SE, Turner RC: Relative hyperproinsulinemia of NIDDM persists despite the reduction of hyperglycemia with insulin or sulfonylurea therapy. Diabetes 46:1557-1562, 1997